NRx Pharmaceuticals, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $126.6M
- Price
- $2.92
- % Change (Daily % change from the live per-ticker quote feed.)
- -0.51%
- Volume
- 330.7K
About
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm focused on developing innovative therapies for disorders of the central nervous system and critical lung diseases. Its product portfolio features ZYESAMI, an experimental medication that has successfully completed Phase IIb/III clinical trials for treating respiratory failure associated with COVID-19. Additionally, the company is advancing NRX-100 and NRX-101, a pair of oral therapeutics designed to address bipolar depression, specifically in patients exhibiting acute or sub-acute suicidal thoughts and behaviors. Established in 2015, NRx Pharmaceuticals is headquartered in Wilmington, Delaware.
Quick stats
Shares outstanding43.3M
Computed float31.0M
Float / shares71.6%
Cash runway (months)11
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001719406
Websitehttps://www.nrxpharma.com
AI Summary
AI-generated1/40
standardbullishoperations update
NRx Defense Systems, an NRx Company (Nasdaq:NRXP) Awarded $11 Million Dollar DARPA Prime Contract to Evaluate Robotic Magnetic Stimulation in conjunction with NRX-101 for Treatment of Resistant Depression
NRx Pharmaceuticals' new subsidiary NRx Defense Systems was awarded an initial $11.18 million DARPA prime contract to evaluate robotic TMS combined with NRX-101 for treatment-resistant depression.
The FDA-approved SPARC-TMS trial (NCT07227103) will enroll at McLean Hospital, Arizona State University, and HOPE Therapeutics, with plans to expand to military hospitals. It tests a single-day TMS protocol augmented by NRX-101, building on prior data showing 91% response and 69% remission at 3 months.
If results replicate, the trial could serve as an FDA registration study for NRX-101 in a population NRx estimates at 8.9 million US adults with a $44 billion burden of illness. The award is non-dilutive and validates the company's defense-contractor pivot, though success in any trial is far from guaranteed.
Red flags
- Clinical-stage company with no approved marketed product; trial success not guaranteed
- Prior 91% response / 69% remission data are from traditional TMS + D-cycloserine, not the exact SPARC-TMS combination being tested